Research graph
References from Better together in NPM1 -mutated AML. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/blood.2026034043 · 2026 · Admitted local publication
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
10.1016/j.cell.2005.09.025 · 2005 · External reference
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
10.1158/2159-8290.cd-16-0237 · 2016 · External reference
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
10.1038/s41375-022-01707-w · 2022 · External reference
Ziftomenib in relapsed or refractory NPM1-mutated AML
10.1200/jco-25-01694 · 2025 · External reference
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
10.1182/bloodadvances.2020003734 · 2021 · External reference
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
10.1182/bloodadvances.2022008316 · 2023 · External reference
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
10.1038/s41375-024-02501-6 · 2025 · External reference
NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed/refractory AML: evidence from the AVALON cohort
10.1002/hon.70169 · 2026 · External reference
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
10.1016/s1470-2045(24)00386-3 · 2024 · External reference
